Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 369 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New study identifies how obesity may increase the risk of developing... April 19, 2022 New on NCI’s Websites for June 2022 June 10, 2022 Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced... August 18, 2026 ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 Load more HOT NEWS FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma Silence Speaks Volumes Aiming to support a robust regulatory ecosystem for driving cancer research... Taking pride in all of our researchers
